1. Clinical case of lung spindle cell carcinoma markedly responsive to pembrolizumab.
- Author
-
Mizushina Y, Ohyanagi F, Shiihara J, Nomura M, Ohta H, Oshiro H, Tsubochi H, Kusaka G, and Yamaguchi Y
- Subjects
- Antineoplastic Agents, Immunological therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, B7-H1 Antigen metabolism, Brain Neoplasms secondary, Carcinoma secondary, Humans, Lung Neoplasms pathology, Male, Middle Aged, Pneumonectomy methods, Thoracic Neoplasms secondary, Antibodies, Monoclonal, Humanized therapeutic use, Brain Neoplasms therapy, Carcinoma therapy, Lung Neoplasms therapy, Thoracic Neoplasms therapy
- Abstract
A 52-year-old man underwent pneumonectomy of the left lung for previously diagnosed primary spindle cell carcinoma (pT4aN1M0, stage III B) with programmed death-ligand 1 expression (tumor proportion score ≥95%) and without epidermal growth factor receptor gene mutation and anaplastic lymphoma kinase fusion gene. However, brain metastasis and chest wall tumor relapse occurred. Considering insufficient improvement with gamma knife treatment for brain metastasis and combination chemotherapy (paclitaxel, carboplatin, and bevacizumab), pembrolizumab monotherapy and palliative irradiation therapy for chest metastases were started after brain tumor volume reduction using craniotomy. Brain edema and chest wall metastases markedly improved following a pseudoprogression of the brain edema accompanied by a performance status decline; this effect continued until 11 cycles of pembrolizumab administration., (© 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.)
- Published
- 2021
- Full Text
- View/download PDF